Exhibit 99.1 AnnualReport2023 Disclaimer PDF print – this document is only a "printed version" and is not the original annual financial reporting including the audited financial statements pursuant to A These original annual financial reporting included in the audited financial statements and the auditor's report thereto, are included in the single report package which can be found at https://www.argenx.com/investors/financial-reports 2023 Annual Report including the Annual Financial Statements for the year ...

ADHERE data presentation will highlight first potential innovation for CIDP patients in 30 years Abstracts reflect real-world value and consistent efficacy and safety profile associated with long-term use of VYVGART® and VYVGART® Hytrulo in gMG patients March 7, 2024, 10:01 pm CET Amsterdam, the Netherlands   – argenx SE ((Euronext &amp, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that eight abstracts, inclu ...

argenx SE (NASDAQ:ARGX) Q4 2023 Results Conference Call February 29, 2024 8:30 AM ET Company Participants Beth DelGiacco - VP and Global Head, Corporate Communications and Investor Relations Tim Van Hauwermeiren - Chief Executive Officer Karl Gubitz - Chief Financial Officer Karen Massey - Chief Operating Officer Conference Call Participants Tazeen Ahmad - Bank of America Derek Archila - Wells Fargo Rajan Sharma - Goldman Sachs Yatin Suneja - Guggenheim Yaron Werber - TD Cowen Allison Bratzel - Piper Sandle ...

$374 million in fourth quarter and $1.2 billion in full year global net product sales sBLA for VYVGART® Hytrulo for CIDP accepted for priority review by FDA with PDUFA target action date of June 21, 2024 On track to report data from six Phase 2 proof-of-concept trials by end of 2024 Management to host conference call today at 2:30 pm CET (8:30 am ET) February 29, 2024, 7:00 am CET Amsterdam, the Netherlands – argenx SE ((Euronext &amp, NASDAQ:ARGX), a global immunology company committed to improving the li ...

Core Viewpoint - Argenx SE (ARGX) is positioned favorably ahead of its upcoming earnings report, with analysts revising earnings estimates upward, indicating potential for an earnings beat [1][2] Earnings Estimates - The Most Accurate Estimate for the current quarter is a loss of 83 cents per share, significantly better than the broader Zacks Consensus Estimate of a loss of $1.23 per share, suggesting positive revisions from analysts [1] - The Zacks Earnings ESP for ARGX stands at +32.48%, indicating strong potential for positive earnings surprises [1] Historical Performance - A positive Zacks Earnings ESP has historically led to positive surprises and outperformance in the market, with a 10-year backtest showing that stocks with a positive Earnings ESP and a Zacks Rank of 3 or better have a nearly 70% chance of delivering a positive surprise and average annual returns exceeding 28% [2] - Given that ARGX holds a Zacks Rank of 3, it is recommended for investors to consider this stock ahead of the earnings report [2]

February 26, 2024Amsterdam, the Netherlands – argenx ((Euronext &amp, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following investor conferences in March: TD Cowen 44th Annual Health Care Conference. Fireside chat on Monday, March 4, 2024 at 11:10 a.m. ET in Boston, MA.Leerink Global Biopharma Conference. Fireside chat on Monday, March 11, 2024 at 2 ...

Core Insights - argenx is a global immunology company focused on improving the lives of individuals with severe autoimmune diseases [2] - The company is participating in several investor conferences in March 2024, including the TD Cowen 44th Annual Health Care Conference, the Leerink Global Biopharma Conference, and the Barclays Global Healthcare Conference [1] Company Overview - argenx partners with leading academic researchers through its Immunology Innovation Program (IIP) to translate immunology breakthroughs into a portfolio of novel antibody-based medicines [2] - The company has developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker in multiple regions including the U.S., Japan, Israel, the EU, the UK, Canada, and China [2] - argenx is evaluating its drug efgartigimod in various serious autoimmune diseases and advancing several earlier-stage experimental medicines within its therapeutic franchises [2]

Company Overview - argenx is a global immunology company focused on improving the lives of individuals suffering from severe autoimmune diseases [2] - The company collaborates with leading academic researchers through its Immunology Innovation Program (IIP) to translate immunology breakthroughs into a portfolio of novel antibody-based medicines [2] - argenx has developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker in multiple regions including the U.S., Japan, Israel, the EU, the UK, Canada, and China [2] Upcoming Events - argenx will host a conference call and audio webcast on February 29, 2024, at 2:30 PM CET (8:30 AM ET) to discuss its full year 2023 financial results and provide a fourth quarter business update [1] - The live call can be accessed on the Investors section of the argenx website, with a replay available for approximately one year following the presentation [1] Product Development - The company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises [2]

Core Viewpoint - The Federal Reserve's potential interest rate cuts may lead to increased investment in riskier sectors, particularly in biotech, which is often speculative due to its reliance on trial results and regulatory approvals [1]. Company Summaries Xenon Pharmaceuticals (XENE) - Xenon Pharmaceuticals is focused on developing neurological therapies, particularly for major depressive disorders, with a key milestone being the XEN1101 Phase 3 Program [2]. - Analysts project a significant earnings per share (EPS) growth of 107.8% over the next 12 months [2]. - The forward price-to-earnings (P/E) ratio is extremely high at 538.0, indicating strong market expectations for future earnings [3]. Argenx (ARGX) - Argenx has a robust product pipeline with over a dozen projects moving towards registration, particularly in autoimmune diseases [5]. - The ARGX-118 project, currently in Phase One, aims to prevent airway inflammation, a growing concern post-COVID-19 [5]. - The stock's forward P/E is 111.7, supported by projected EPS growth of approximately 240.0% in the coming year [6]. IntraCellular Therapies (ITCI) - IntraCellular Therapies focuses on neurological disorders, including bipolar depression and Parkinson's disease, primarily in the U.S. market [7]. - The company has the lowest forward P/E among the three at 88.8, but still shows strong potential for growth [7]. - Analysts anticipate an impressive EPS growth of 225.8% this year, driven by the Lumateperone pipeline nearing the end of Phase 3 trials [8].

Prescription Drug User Fee Act (PDUFA) target action date is June 21, 2024 If approved, VYVGART® Hytrulo will be the first neonatal Fc receptor (FcRn) blocker to treat CIDP February 20, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &amp, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a supplemental Biologics ...